News

Epicore Launches Wearable Patch to Analyze Sweat of CF Patients

Epicore Biosystems has launched in the U.S. a wearable patch allowing it to collect and analyze sweat for biomarker research, the company announced. Called the Discovery Patch Sweat Collection System, it may be useful in monitoring changes in sweat chloride in people with cystic fibrosis (CF), among other applications.

New Data-sharing Program Aims to Speed Innovation in Rare Diseases

A new U.S. initiative called Rare Disease Cures Accelerator–Data and Analytics Platform — dubbed RDCA–DAP — aims to accelerate treatment innovation across rare diseases by sharing existing patient data and promoting the standardization of new data collection. Launched during a virtual workshop in September, the U.S. Food and Drug…

Elixir Chooses Maxor Specialty as CF Medication Provider

Pharmacy benefits and services company Elixir has chosen Maxor Specialty Pharmacy to be its network’s exclusive provider of medications for cystic fibrosis (CF). Maxor Specialty specializes in rare diseases like CF and is one of four pharmacies in the U.S. to have access to all medications approved for cystic fibrosis,…

Phase 1 Study of KB407 Green-lighted in Australia

A research ethics committee in Australia has given Krystal Biotech the go-ahead to start a Phase 1 clinical study of KB407, the company’s investigational inhaled gene therapy for cystic fibrosis (CF). Enrollment for the trial is expected to start soon, according to Krystal, following approval from the…

Trikafta Now Covered in 2 More Canadian Provinces

The publicly funded drug access programs in the Canadian provinces of Alberta and Saskatchewan are now covering the triple-combination therapy Trikafta for eligible patients with cystic fibrosis (CF). These provinces join Ontario as the first to confirm coverage of Trikafta in Canada. “It’s a relief to know that…